10037 Background: Racial and ethnic survival disparities have been described for many pediatric malignancies, but the impact of income has not been extensively explored. To assess whether socioeconomic status affects outcomes, we evaluated low-income public health insurance as a proxy. We analyzed how low-income public health insurance influences overall survival in children, adolescents, and young adults diagnosed with bone and soft tissue sarcomas. Methods: The University of California San Francisco Cancer Registry was used to identify patients age 0-39 diagnosed with bone or soft tissue sarcomas between 2000-2015. Low-income patients were defined as those with Medicaid, which is only available under state law to eligible low-income individuals or families, or those with no insurance. The comparison group included all other patients with private insurance, Medicare, or Tricare. Survival curves were computed using the Kaplan-Meier method and compared using log-rank tests and Cox models. Logistic regression was used to investigate the association of low-income public insurance and presence of metastatic disease at diagnosis. Results: A total of 1,106 patients were included in the analysis. 444 (40%) were considered low-income; of these, 428 (39%) had public insurance and 16 (1%) had no insurance. Low-income patients were more likely to both be racial/ethnic minorities and present with metastatic disease on multivariable analysis. Low-income patients had significantly worse 5-year OS (61% vs 71%, p = 0.0003). When stratified by localized, regional, or metastatic disease, low-income patients consistently had significantly worse 5-year OS (localized: 78% vs 84%, regional: 64% vs 73%, metastatic: 23% vs 30% respectively, p < 0.0001). Age and race/ethnicity did not significantly impact OS in this study population. Conclusions: Low-income patients with bone and soft tissue sarcomas had decreased overall survival. While these patients were more likely to have metastatic disease, disparities in survival were noted even within the localized and regional disease groups. The means by which insurance status impacts survival requires additional investigation, but may be through reduced access to care.